Covered recipient · General Payments record
APARNA TAMIRISA
Allopathic & Osteopathic Physicians Internal Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$436.11
29 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $436.11 | 29 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Horizon Therapeutics plc | $111.82 | 11 |
| Amgen Inc. | $75.21 | 4 |
| Novo Nordisk Inc | $43.54 | 2 |
| AbbVie Inc. | $41.89 | 2 |
| Optinose US, Inc. | $38.38 | 2 |
| Lilly USA, LLC | $29.96 | 2 |
| Kowa Pharmaceuticals America, Inc. | $26.30 | 2 |
| Bayer HealthCare Pharmaceuticals Inc. | $23.72 | 1 |
| Amarin Pharma Inc. | $19.56 | 1 |
| Esperion Therapeutics, Inc. | $14.22 | 1 |
| AstraZeneca Pharmaceuticals LP | $11.51 | 1 |
Page 1 of 1; records 1–29 of 29 matching records. This page contains 29 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
APARNA TAMIRISA
NPI 1124273974 · CMS profile ID 6084
Allopathic & Osteopathic Physicians / Internal Medicine
SUGAR LAND, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–29 of 29 matching records. This page contains 29 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1124273974?year=2021&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- APARNA TAMIRISA, NPI 1124273974, CMS profile ID 6084. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–29 of 29 matching records. This page contains 29 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124273974?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). APARNA TAMIRISA, NPI 1124273974, CMS profile ID 6084. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–29 of 29 matching records. This page contains 29 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124273974?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- APARNA TAMIRISA, NPI 1124273974, CMS profile ID 6084, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–29 of 29 matching records. This page contains 29 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1124273974?year=2021&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
29 matching records · $436.11 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–29 of 29.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Horizon Therapeutics plc | $12.61 | 12/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797216635 | CMS |
| AstraZeneca Pharmaceuticals LP | $11.51 | 12/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834346235 | CMS |
| Optinose US, Inc. | $20.43 | 12/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851668289 | CMS |
| Horizon Therapeutics plc | $14.30 | 12/06/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797216633 | CMS |
| Optinose US, Inc. | $17.95 | 11/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 851668299 | CMS |
| Amgen Inc. | $14.02 | 11/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826296735 | CMS |
| Amgen Inc. | $20.30 | 11/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 826296739 | CMS |
| Horizon Therapeutics plc | $9.28 | 11/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797216629 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $23.72 | 11/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 789185571 | CMS |
| Horizon Therapeutics plc | $5.16 | 10/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797216627 | CMS |
| Horizon Therapeutics plc | $10.61 | 10/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797216623 | CMS |
| Lilly USA, LLC | $14.69 | 10/07/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818958559 | CMS |
| Kowa Pharmaceuticals America, Inc. | $11.43 | 09/08/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 805590297 | CMS |
| Horizon Therapeutics plc | $6.93 | 09/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797216619 | CMS |
| Amarin Pharma Inc. | $19.56 | 09/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 815269897 | CMS |
| Lilly USA, LLC | $15.27 | 08/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818958555 | CMS |
| Horizon Therapeutics plc | $17.79 | 07/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797216617 | CMS |
| Amgen Inc. | $20.89 | 06/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825155453 | CMS |
| Esperion Therapeutics, Inc. | $14.22 | 06/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 838418741 | CMS |
| Horizon Therapeutics plc | $5.07 | 05/17/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797216613 | CMS |
| Horizon Therapeutics plc | $6.83 | 04/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797216611 | CMS |
| AbbVie Inc. | $18.49 | 04/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 796133637 | CMS |
| Kowa Pharmaceuticals America, Inc. | $14.87 | 04/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 805590303 | CMS |
| AbbVie Inc. | $23.40 | 03/31/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 796133635 | CMS |
| Horizon Therapeutics plc | $10.32 | 03/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797216607 | CMS |
| Novo Nordisk Inc | $20.71 | 02/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829454863 | CMS |
| Amgen Inc. | $20.00 | 02/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825155449 | CMS |
| Novo Nordisk Inc | $22.83 | 01/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 829436067 | CMS |
| Horizon Therapeutics plc | $12.92 | 01/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 797216605 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $417,693.13 | 33 |
| PY2024 | Principal investigator | $337,941.60 | 29 |
| PY2023 | Principal investigator | $114,419.07 | 43 |
| PY2022 | Principal investigator | $112,985.59 | 129 |
| PY2021 | Principal investigator | $135,746.11 | 40 |
| PY2020 | Principal investigator | $314,454.61 | 68 |
| PY2019 | Principal investigator | $340,052.76 | 93 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
93 records in PY2019
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Novo Nordisk AS | $675.57 | 12/23/2019 | Non-covered Recipient Entity HOUSTON CENTER FOR CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 692453917 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $303.00 | 12/20/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | Bay1002670 Fibroids Efficacy US / CN | No dispute reported | 06/30/2026 | 629186809 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $303.00 | 12/20/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | Bay1002670 Fibroids Efficacy US / CN | No dispute reported | 06/30/2026 | 629187769 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $368.00 | 12/17/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | BAY 94-8862 ph 3 conventional in diab nephropathy | No dispute reported | 06/30/2026 | 629186655 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $1,334.00 | 12/16/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | BAY94-8862 ph 3 conventional in diabetic nephropathy | No dispute reported | 06/30/2026 | 629186983 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $1,334.00 | 12/16/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | BAY94-8862 ph 3 conventional in diabetic nephropathy | No dispute reported | 06/30/2026 | 629187505 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $116.00 | 12/16/2019 | Non-covered Recipient Entity HOUSTON CENTER FOR CLINICAL RESEARCH | POST-AUTHORISATION SAFETY (PAS) OBSERVATIONAL COHORT STUDY TO QUANTIFY | No dispute reported | 06/30/2026 | 669974515 |
| Principal investigator 1 | AbbVie, Inc. | $5,194.38 | 12/13/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | M16-283 | No dispute reported | 06/30/2026 | 647611797 |
| Principal investigator 1 | Novo Nordisk AS | $24.99 | 12/06/2019 | Non-covered Recipient Entity HOUSTON CENTER FOR CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 706688345 |
| Principal investigator 1 | Novo Nordisk AS | $720.57 | 12/03/2019 | Non-covered Recipient Entity HOUSTON CENTER FOR CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 692453915 |
| Principal investigator 1 | AbbVie, Inc. | $18,738.84 | 11/25/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | M16-283 | No dispute reported | 06/30/2026 | 647611799 |
| Principal investigator 1 | Bausch Health US, LLC | $450.00 | 11/09/2019 | Non-covered Recipient Entity HOUSTON CENTER FOR CLINICAL RESEARCH | A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2 ARM, PARALLEL GROUP STUDY COMPARING THE SAFETY AND EFFICACY OF IDP-123 LOTION AND IDP-123 VEHICLE LOTION IN THE TREATMENT OF ACNE VULGARIS | No dispute reported | 06/30/2026 | 684366045 |
| Principal investigator 1 | Novo Nordisk AS | $675.57 | 10/29/2019 | Non-covered Recipient Entity HOUSTON CENTER FOR CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 692453911 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $2,018.00 | 10/25/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | BAY94-8862 ph 3 conventional in diabetic nephropathy | No dispute reported | 06/30/2026 | 629187079 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $2,018.00 | 10/25/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | BAY94-8862 ph 3 conventional in diabetic nephropathy | No dispute reported | 06/30/2026 | 629187747 |
| Principal investigator 1 | AbbVie, Inc. | $432.30 | 10/24/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | M16-283 | No dispute reported | 06/30/2026 | 647611795 |
| Principal investigator 1 | AbbVie, Inc. | $14,298.21 | 09/30/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | M16-283 | No dispute reported | 06/30/2026 | 647611793 |
| Principal investigator 1 | Novo Nordisk AS | $2,333.26 | 09/26/2019 | Non-covered Recipient Entity HOUSTON CENTER FOR CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 692453913 |
| Principal investigator 1 | Novo Nordisk AS | $9.99 | 08/30/2019 | Non-covered Recipient Entity HOUSTON CENTER FOR CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 706688355 |
| Principal investigator 1 | Novo Nordisk AS | $3.66 | 08/30/2019 | Non-covered Recipient Entity HOUSTON CENTER FOR CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 706688357 |
| Principal investigator 1 | Novo Nordisk AS | $10.99 | 08/30/2019 | Non-covered Recipient Entity HOUSTON CENTER FOR CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 706688359 |
| Principal investigator 1 | Novo Nordisk AS | $12.98 | 08/30/2019 | Non-covered Recipient Entity HOUSTON CENTER FOR CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 706688361 |
| Principal investigator 1 | AbbVie, Inc. | $1,925.92 | 08/29/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | M16-283 | No dispute reported | 06/30/2026 | 647611791 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $2,018.00 | 08/23/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | BAY94-8862 ph 3 conventional in diabetic nephropathy | No dispute reported | 06/30/2026 | 629186733 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $2,018.00 | 08/23/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | BAY94-8862 ph 3 conventional in diabetic nephropathy | No dispute reported | 06/30/2026 | 629187247 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $2,018.00 | 08/23/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | BAY94-8862 ph 3 conventional in diabetic nephropathy | No dispute reported | 06/30/2026 | 629187273 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $1,485.00 | 08/14/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | Bay1002670 Fibroids Efficacy US / CN | No dispute reported | 06/30/2026 | 629186695 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $1,485.00 | 08/14/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | Bay1002670 Fibroids Efficacy US / CN | No dispute reported | 06/30/2026 | 629187659 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $19.00 | 08/08/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | Bay1002670 Fibroids Efficacy US / CN | No dispute reported | 06/30/2026 | 629186575 |
| Principal investigator 1 | Novo Nordisk AS | $24.99 | 08/02/2019 | Non-covered Recipient Entity HOUSTON CENTER FOR CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 706688353 |
| Principal investigator 1 | AbbVie, Inc. | $216.15 | 07/30/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | M16-283 | No dispute reported | 06/30/2026 | 647611789 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $368.00 | 07/17/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | BAY 94-8862 ph 3 conventional in diab nephropathy | No dispute reported | 06/30/2026 | 629187549 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $1,334.00 | 07/17/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | BAY94-8862 ph 3 conventional in diabetic nephropathy | No dispute reported | 06/30/2026 | 629187615 |
| Principal investigator 1 | Dr.Reddy's Laboratories,Inc. | $4,131.70 | 07/09/2019 | Non-covered Recipient Entity HOUSTON CENTER FOR CLINICAL RESEARCH | Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 701425653 |
| Principal investigator 1 | Dr.Reddy's Laboratories,Inc. | $4,400.00 | 07/01/2019 | Non-covered Recipient Entity HOUSTON CENTER FOR CLINICAL RESEARCH | Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 701425637 |
| Principal investigator 1 | Dr.Reddy's Laboratories,Inc. | $50.00 | 07/01/2019 | Non-covered Recipient Entity HOUSTON CENTER FOR CLINICAL RESEARCH | Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 701425639 |
| Principal investigator 1 | Dr.Reddy's Laboratories,Inc. | $450.00 | 07/01/2019 | Non-covered Recipient Entity HOUSTON CENTER FOR CLINICAL RESEARCH | Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 701425641 |
| Principal investigator 1 | AbbVie, Inc. | $21,374.44 | 06/27/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | M16-283 | No dispute reported | 06/30/2026 | 647611787 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $1,210.00 | 06/17/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | Bay1002670 Fibroids Efficacy US / CN | No dispute reported | 06/30/2026 | 629186845 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $1,210.00 | 06/17/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | Bay1002670 Fibroids Efficacy US / CN | No dispute reported | 06/30/2026 | 629187703 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $2,018.00 | 06/06/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | BAY94-8862 ph 3 conventional in diabetic nephropathy | No dispute reported | 06/30/2026 | 629186881 |
| Principal investigator 1 | AbbVie, Inc. | $2,610.76 | 05/29/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | M16-283 | No dispute reported | 06/30/2026 | 647611785 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $1,373.00 | 05/16/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | BAY94-8862 ph 3 conventional in diabetic nephropathy | No dispute reported | 06/30/2026 | 629186915 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $1,659.00 | 05/16/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | BAY94-8862 ph 3 conventional in diabetic nephropathy | No dispute reported | 06/30/2026 | 629187109 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $1,334.00 | 05/16/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | BAY94-8862 ph 3 conventional in diabetic nephropathy | No dispute reported | 06/30/2026 | 629187593 |
| Principal investigator 1 | Novo Nordisk AS | $3,000.00 | 05/07/2019 | Non-covered Recipient Entity HOUSTON CENTER FOR CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 692453907 |
| Principal investigator 1 | Novo Nordisk AS | $500.00 | 05/07/2019 | Non-covered Recipient Entity HOUSTON CENTER FOR CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 692453909 |
| Principal investigator 1 | AbbVie, Inc. | $1,061.32 | 04/29/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | M16-283 | No dispute reported | 06/30/2026 | 647611781 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $461.00 | 04/11/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | BAY 94-8862 ph 3 conventional in diab nephropathy | No dispute reported | 06/30/2026 | 629187637 |
| Principal investigator 1 | AbbVie, Inc. | $350.00 | 04/08/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | M12-815 | No dispute reported | 06/30/2026 | 647611771 |
| Principal investigator 1 | AbbVie, Inc. | $690.00 | 04/08/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | M12-815 | No dispute reported | 06/30/2026 | 647611773 |
| Principal investigator 1 | Dr.Reddy's Laboratories,Inc. | $765.90 | 04/08/2019 | Non-covered Recipient Entity HOUSTON CENTER FOR CLINICAL RESEARCH | Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 701425579 |
| Principal investigator 1 | AbbVie, Inc. | $1,500.00 | 04/04/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | M12-815 | No dispute reported | 06/30/2026 | 647611775 |
| Principal investigator 1 | AbbVie, Inc. | $1,500.00 | 04/04/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | M12-815 | No dispute reported | 06/30/2026 | 647611777 |
| Principal investigator 1 | AbbVie, Inc. | $1,500.00 | 04/04/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | M12-815 | No dispute reported | 06/30/2026 | 647611779 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $1,334.00 | 04/04/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | BAY94-8862 ph 3 conventional in diabetic nephropathy | No dispute reported | 06/30/2026 | 629186771 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $1,334.00 | 04/04/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | BAY94-8862 ph 3 conventional in diabetic nephropathy | No dispute reported | 06/30/2026 | 629187221 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $1,334.00 | 04/04/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | BAY94-8862 ph 3 conventional in diabetic nephropathy | No dispute reported | 06/30/2026 | 629187571 |
| Principal investigator 1 | Novo Nordisk AS | $117.78 | 04/04/2019 | Non-covered Recipient Entity HOUSTON CENTER FOR CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 706688349 |
| Principal investigator 1 | Novo Nordisk AS | $75.00 | 04/03/2019 | Non-covered Recipient Entity HOUSTON CENTER FOR CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 706688351 |
| Principal investigator 1 | AbbVie, Inc. | $11,959.20 | 04/01/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | M16-283 | No dispute reported | 06/30/2026 | 647611783 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $9,697.00 | 03/21/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | Bay1002670 Fibroids Efficacy US / CN | No dispute reported | 06/30/2026 | 629187015 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $50.00 | 03/21/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | Bay1002670 Fibroids Efficacy US / CN | No dispute reported | 06/30/2026 | 629187193 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $1,780.00 | 03/21/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | Bay1002670 Fibroids Efficacy US / CN | No dispute reported | 06/30/2026 | 629187329 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $810.00 | 03/21/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | Bay1002670 Fibroids Efficacy US / CN | No dispute reported | 06/30/2026 | 629187357 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $500.00 | 03/21/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | Bay1002670 Fibroids Efficacy US / CN | No dispute reported | 06/30/2026 | 629187385 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $1,000.00 | 03/21/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | Bay1002670 Fibroids Efficacy US / CN | No dispute reported | 06/30/2026 | 629187413 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $1,375.00 | 03/21/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | Bay1002670 Fibroids Efficacy US / CN | No dispute reported | 06/30/2026 | 629187461 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $728.00 | 03/21/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | Bay1002670 Fibroids Efficacy US / CN | No dispute reported | 06/30/2026 | 629187483 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $270.00 | 03/21/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | Bay1002670 Fibroids Efficacy US / CN | No dispute reported | 06/30/2026 | 629187527 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $100.00 | 03/21/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | Bay1002670 Fibroids Efficacy US / CN | No dispute reported | 06/30/2026 | 629187791 |
| Principal investigator 1 | AbbVie, Inc. | $53,643.94 | 03/19/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | M16-283 | No dispute reported | 06/30/2026 | 647611765 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $371.00 | 03/15/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | Bay1002670 Fibroids Efficacy US / CN | No dispute reported | 06/30/2026 | 629186615 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $758.00 | 03/15/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | Bay1002670 Fibroids Efficacy US / CN | No dispute reported | 06/30/2026 | 629186949 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $758.00 | 03/15/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | Bay1002670 Fibroids Efficacy US / CN | No dispute reported | 06/30/2026 | 629187047 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $641.00 | 03/15/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | Bay1002670 Fibroids Efficacy US / CN | No dispute reported | 06/30/2026 | 629187165 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $1,513.00 | 03/15/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | Bay1002670 Fibroids Efficacy US / CN | No dispute reported | 06/30/2026 | 629187681 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $371.00 | 03/15/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | Bay1002670 Fibroids Efficacy US / CN | No dispute reported | 06/30/2026 | 629187725 |
| Principal investigator 1 | Bausch Health US, LLC | $1,042.50 | 03/07/2019 | Non-covered Recipient Entity HOUSTON CENTER FOR CLINICAL RESEARCH | A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, 2 ARM, PARALLEL GROUP STUDY COMPARING THE SAFETY AND EFFICACY OF IDP-123 LOTION AND IDP-123 VEHICLE LOTION IN THE TREATMENT OF ACNE VULGARIS | No dispute reported | 06/30/2026 | 684348887 |
| Principal investigator 1 | Dr.Reddy's Laboratories,Inc. | $1,444.50 | 03/01/2019 | Non-covered Recipient Entity HOUSTON CENTER FOR CLINICAL RESEARCH | Randomized,Doube-Blind, Placebo-Controlled, Multicenter, 24 week study to assess the Efficacy and Safety of PPC-06, extended release tablets in Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 701425695 |
| Principal investigator 1 | AbbVie, Inc. | $1,042.76 | 02/28/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | M16-283 | No dispute reported | 06/30/2026 | 647611757 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $1,334.00 | 02/14/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | BAY94-8862 ph 3 conventional in diabetic nephropathy | No dispute reported | 06/30/2026 | 629187813 |
| Principal investigator 1 | Novo Nordisk AS | $1.70 | 02/08/2019 | Non-covered Recipient Entity HOUSTON CENTER FOR CLINICAL RESEARCH | EX9536-4388 | No dispute reported | 06/30/2026 | 706688347 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $72,289.21 | 02/05/2019 | Non-covered Recipient Entity Interspond - Houston Center For Clinical Research | A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to | No dispute reported | 06/30/2026 | 639761893 |
| Principal investigator 1 | AbbVie, Inc. | $490.00 | 02/01/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | M16-283 | No dispute reported | 06/30/2026 | 647611759 |
| Principal investigator 1 | AbbVie, Inc. | $1,500.00 | 02/01/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | M16-283 | No dispute reported | 06/30/2026 | 647611761 |
| Principal investigator 1 | AbbVie, Inc. | $1,120.00 | 02/01/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | M16-283 | No dispute reported | 06/30/2026 | 647611763 |
| Principal investigator 1 | AbbVie, Inc. | $8,520.47 | 01/29/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | M16-283 | No dispute reported | 06/30/2026 | 647611767 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $542.00 | 01/15/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | Bay1002670 Fibroids Efficacy US / CN | No dispute reported | 06/30/2026 | 629187137 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $2,432.00 | 01/15/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | Bay1002670 Fibroids Efficacy US / CN | No dispute reported | 06/30/2026 | 629187439 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $22,832.28 | 01/15/2019 | Non-covered Recipient Entity HOUSTON CENTER FOR CLINICAL RESEARCH | MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED 52 WEEK STUDY TO DEMONSTRATE THE EFFICACY SAFETY AND TOLERABILITY OF SECUKINUMAB INJECTIONS WITH 2 ML AUTO INJECTORS 300 MG IN ADULT SUBJECTS WITH PLAQUE PSORIASIS | No dispute reported | 06/30/2026 | 640717441 |
| Principal investigator 1 | Bayer HealthCare Pharmaceuticals Inc. | $1,334.00 | 01/09/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | BAY94-8862 ph 3 conventional in diabetic nephropathy | No dispute reported | 06/30/2026 | 629187301 |
| Principal investigator 1 | AbbVie, Inc. | $16,170.93 | 01/02/2019 | Non-covered Recipient Entity Houston Center For Clinical Research | M16-283 | No dispute reported | 06/30/2026 | 647611769 |